Wolfgang Dummer - 24 Jan 2022 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP & CMO
Signature
/s/ Dolly Vance (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
24 Jan 2022
Net transactions value
$0
Form type
4
Filing time
26 Jan 2022, 19:46:09 UTC
Previous filing
05 Nov 2021
Next filing
30 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +50,000 +280% $0.000000 67,848 24 Jan 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 24 Jan 2022 Common Stock 100,000 $2.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023.
F2 Includes 17,848 shares acquired under the Issuer's stock purchase plan.
F3 The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period